Skip to main content
Scroll Top
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Menu
WHO WE ARE
ABOUT US
TEAM
MANAGEMENT TEAM
INDUSTRIAL ADVISORS
SCIENTIFIC COUNCIL
PARTNERS
R&D
INTRODUCTION
TECH
NEUROSTIMULATION
PHOTOBIOMODULATION
ALZHEIMER
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
CONCUSSION
CLINICAL TRIAL
PATHOPHYSIOLOGY
TECHNOLOGY
SOLUTIONS
CLINICAL RESEARCH
PRECLINICAL RESEARCH
CONCUSSION
NEWS
ALL
PRESS ARTICLES
VIDEOS
EVENTS
SCIENTIFIC PUBLICATIONS
ALL
SCIENTIFIC ARTICLES
ORAL COMMUNICATIONS
POSTED COMMUNICATIONS
CONTACT
FAQ
Executive summary
Français
Home
Alzheimer
Neuroprotective effect of novel photobiomodulation technology reduces microbiota dysbiosis in the Aβ25-35 mouse model
Most Viewed Posts
Clear Filters
Alzheimer’s: REGEnLIFE opens two new centres in Paris for its clinical trial
15 March 2026
Alzheimer’s disease: an innovative non-drug trial gets underway in Toulouse
25 September 2023
A promising new treatment for concussion and Alzheimer’s victims?
26 September 2024
30 January 2019
Neuroprotective effect of novel photobiomodulation technology reduces microbiota dysbiosis in the Aβ25-35 mouse model
Club Alzheimer de Montpellier (CALM) 2019, Montpellier
Read the article
Laura Auboyer
Share this article
alzheimer
Oral Communications
Post navigation
Previous post
Designing a unique treatment protocol by assessing efficient photonic and magnetic emission parameters on an Alzheimer’s disease animal model
Next post
REGENLIFE: “Product or service of the future” award, Les Inn’Ovations 2019 competition
Get a Quote
